GE Healthcare has unveiled a new generative AI (genAI) platform, CareIntellect for Oncology, which will be available for commercial use in the US next year for prostate and breast cancer use.
The platform can organise structured and unstructured data such as medical images, records, and notes, as well as summarise medical histories. GE notes that the system can also support treatment response assessments, help assess clinical trial eligibility, and track adherence to treatment protocols in an easy-to-navigate view.
While the system will initially focus on prostate and breast cancer indications, the company intends to expand to other oncological indications. GE also plans to market the platform in Canada, UK, and Ireland. The platform is being evaluated in two US sites, Tampa General Hospital and UT Southwestern Medical Center.
GE noted that the CareIntellect system can “provide care with a concise view of the patient’s progressive treatment journey” and can flag any deviation from adherence to the treatment plan. The system uses a cloud-first digital infrastructure to allow for easier onboarding and allows for easier integration of additional products.
“Currently only 3% of hospital data is used because of the complexities associated with organising and extracting useful healthcare insights at scale. Yet there is so much potential to turn the other 97% into actionable data to advance healthcare, but it is critical that any new technologies we develop be efficient and easy to use while reducing cognitive burdens for clinicians and removing implementation hurdles for providers,” said Dr Taha Kass-Hout, global chief science, and technology officer at GE Healthcare.
GlobalData expects the global revenue for AI platforms across healthcare to reach an estimated $18.8bn by 2027. The total specialised AI application market is estimated to be worth $477.6bn in 2030.
GE has invested heavily in developing AI products. In July, the company partnered with Amazon Web Services to build new genAI models that can analyse complex medical data. The same month, GE paid £40.5m ($51m) to acquire the AI ultrasound business of Welsh Intelligent Ultrasound Group.
